IFNγ signaling integrity in colorectal cancer immunity and immunotherapy

The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFN gamma) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFN gamma signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFN gamma signaling to inform novel clinical trials to treat patients with colorectal cancer.

Automated summary

The majority of colorectal cancer patients do not respond to immune checkpoint blockade, with the IFN gamma signaling pathway playing a crucial role in antitumor immunity. Targeting IFN gamma signaling for novel clinical trials in treating patients with colorectal cancer is of significant importance.